ArticlebioRxiv : the preprint server for biology2024
A highly potent, orally bioavailable pyrazole-derived cannabinoid CB2 receptor-selective full agonist for
Andrea Chicca, Daniel Batora, Christoph Ullmer, Antonello Caruso, Jürgen Fingerle, Thomas Hartung, Roland Degen, Matthias Müller, Uwe Grether, Pal Pacher and 1 more
Abstract readPreprint
In one paragraphArticle in bioRxiv : the preprint server for biology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
5 · Who and what moneyAuthors and funding
11 authors.
Andrea ChiccaInstitute of Biochemistry and Molecular Medicine, University of Bern, Bern 3012, Switzerland.ORCID 0000-0001-9593-636X Daniel BatoraInstitute of Biochemistry and Molecular Medicine, University of Bern, Bern 3012, Switzerland.ORCID 0000-0001-8605-9844 Christoph UllmerPharmaceutical Sciences, Roche Innovation Center Basel, Roche Pharma Research and Early Development, Basel 4070, Switzerland.ORCID 0000-0002-1044-6722 Antonello CarusoPharmaceutical Sciences, Roche Innovation Center Basel, Roche Pharma Research and Early Development, Basel 4070, Switzerland.ORCID 0000-0001-5832-3636 Jürgen FingerlePharmaceutical Sciences, Roche Innovation Center Basel, Roche Pharma Research and Early Development, Basel 4070, Switzerland.ORCID 0000-0003-4925-7459 Thomas HartungPharmaceutical Sciences, Roche Innovation Center Basel, Roche Pharma Research and Early Development, Basel 4070, Switzerland.
Roland DegenPharmaceutical Sciences, Roche Innovation Center Basel, Roche Pharma Research and Early Development, Basel 4070, Switzerland.
Matthias MüllerPharmaceutical Sciences, Roche Innovation Center Basel, Roche Pharma Research and Early Development, Basel 4070, Switzerland.
Uwe GretherPharmaceutical Sciences, Roche Innovation Center Basel, Roche Pharma Research and Early Development, Basel 4070, Switzerland.ORCID 0000-0002-3164-9270 Pal PacherLaboratory of Cardiovascular Physiology and Tissue Injury (P.P.), National Institute on Alcohol Abuse and Alcoholism, National Institutes of Health (NIH), Bethesda, MD.ORCID 0000-0001-7036-8108 Jürg GertschInstitute of Biochemistry and Molecular Medicine, University of Bern, Bern 3012, Switzerland.ORCID 0000-0003-0978-1555 Funding
No grant is acknowledged in the PubMed record.
6 · The paper itselfAbstract
The cannabinoid CB2 receptor (CB2R) is a potential therapeutic target for distinct forms of tissue injury and inflammatory diseases. To thoroughly investigate the role of CB2R in pathophysiological conditions and for target validation
Identifiers
PMID38903103
PMCPMC11188143
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390